Qtron Investments’s Royalty Pharma RPRX Stock Holding History

Qtron Investments’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$865K	Sell	15,431 -3,050	-17%	-$159K	0.12%	205
2026 Q1	$887K	Buy	18,481 +2,063	+13%	+$90.4K	0.12%	212
2025 Q4	$634K	Buy	16,418 +2,178	+15%	+$83.1K	0.08%	270
2025 Q3	$502K	Buy	14,240 +2,938	+26%	+$106K	0.06%	327
2025 Q2	$407K	Buy	+11,302	New	+$374K	0.05%	362
2023 Q1	–	Sell	-9,895	Closed	-$391K	–	450
2022 Q4	$391K	Hold	9,895	–	–	0.08%	301
2022 Q3	$398K	Buy	+9,895	New	+$423K	0.1%	276

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Qtron Investments's RPRX Position: Q2 2026 in Review

Qtron Investments reduced its Royalty Pharma (RPRX) stake by 17% in Q2 2026, selling an estimated $159K and leaving 15,431 shares worth $865K. The position accounts for 0.12% of the portfolio, ranked #205.

Qtron Investments first reported a position in RPRX in Q3 2022 and has held it in 7 quarters since. The position peaked at $887K in Q1 2026. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Qtron Investments held 15,431 shares of Royalty Pharma worth $865K as of Q2 2026.
Qtron Investments sold 3,050 Royalty Pharma shares in Q2 2026, an estimated $159K.
Royalty Pharma made up 0.12% of Qtron Investments's portfolio in Q2 2026, its #205 holding.
Qtron Investments first reported a position in Royalty Pharma in Q3 2022 and has held it in 7 quarters since.
Qtron Investments's Royalty Pharma position peaked at $887K in Q1 2026.
646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Qtron Investments's 13F filing for Q2 2026, filed 13 Aug 2026.